Brain positron emission tomography
Brain positron emission tomography | |
---|---|
ICD-10-PCS | C030 |
Brain positron emission tomography is a form of
Process
The
Advantages and disadvantages
The greatest benefit of PET scanning is that different compounds can show
Uses
Before the use of
PET scanning is also used for diagnosis of brain disease, most notably because brain tumors, strokes, and neurondegenerative diseases (such as Alzheimer's disease and Parkinson's disease) all cause great changes in brain metabolism, which in turn causes detectable changes in PET scans. PET is probably most useful in early cases of certain dementias (with classic examples being
PET is also actively used for multiple sclerosis and other acquired demyelinating syndromes, but mainly for research into pathogenesis instead of diagnosis. They use specific radioligands for microglial activity. Currently is widely used the 18-kDa translocator protein (TSPO).[5] Also combined PET-CT are sometimes performed.[6]
Tracer Types
PET imaging with oxygen-15 indirectly measures blood flow to the brain. In this method, increased radioactivity signal indicates increased blood flow which is assumed to correlate with increased brain activity. Because of its 2-minute half-life, O-15 must be piped directly from a medical cyclotron for such uses, which is difficult.
PET imaging with 18F-FDG takes advantage of the fact that the brain is normally a rapid user of glucose. Standard 18F-FDG PET of the brain measures regional glucose use and can be used in neuropathological diagnosis.
- Example: Brain pathologies such as amyloid-betaplaques (a potential biomarker for Alzheimer's) in the brain.
- Examples: PET imaging with FDG can also be used for localization of seizure focus: A seizure focus will appear as hypometabolic during an interictal scan. Several FDOPA for the AADC enzyme). These agents permit the visualization of neuroreceptor pools in the context of a plurality of neuropsychiatric and neurologic illnesses.
- Example: PET imaging with 18F-FDG can be used to estimate glucose metabolism in acute ischemic stroke.[7] Some traces used for ischemic stroke are Oxygen-15 labelled water, [18F]FMISO.[8][9]
The development of a number of novel probes for noninvasive, in vivo PET imaging of neuroaggregate in human brain has brought amyloid imaging to the doorstep of clinical use. The earliest amyloid imaging probes included 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP)
Dedicated Brain PET Devices
In 2019 Catana et al.[14] published an overview article about the "Development of Dedicated Brain PET Imaging Devices: Recent Advances and Future Perspectives". Various companies worldwide are working on developing a dedicated brain PET system either for pure research and/or clinical routine use. One of these companies is Positrigo which is working on the NeuroLF system.
Challenges
One main challenge for developing new PET tracers for neuroimaging is that these tracers must cross the blood-brain barrier. Commonly, small molecules which are fat soluble have been used as they can pass the blood-brain barrier through lipid mediated passive diffusion.
However, as pharmaceutics move towards large biomolecules for therapies, new research has also focused on using biomolecules, such as antibodies, for PET tracers. These new larger PET tracers have increased difficulty passing the BBB as they are too large to passively diffuse across. Therefore, recent research is investigating methods to carry biomolecules across the BBB using endogenous transport systems including carrier-mediated transporters such as glucose and amino acid carriers, receptor-mediated transcytosis for insulin or transferrin.[15]
References
- ^ a b Nilsson LG, Markowitsch HJ (1999). Cognitive Neuroscience of Memory. Seattle: Hogrefe & Huber Publishers. p. 57.
- OCLC 437345781.[page needed]
- PMID 12750391.
- PMID 15235060.
- PMID 29632509.
- PMID 29215409.
- NAID 10025136171.
- PMID 10429709.
- S2CID 34075.
- PMID 11734604.
- PMID 11814781.
- S2CID 11057426.
- ^ Kolata, Gina (24 June 2010). "Promise Seen for Detection of Alzheimer's". The New York Times.
- PMID 31028166.
- PMID 31342134.